Table of Contents Author Guidelines Submit a Manuscript
Journal of Nutrition and Metabolism
Volume 2011 (2011), Article ID 369168, 7 pages
http://dx.doi.org/10.1155/2011/369168
Research Article

Evaluation of Biomarkers of NAFLD in a Cohort of Morbidly Obese Patients

1Division of Gastroenterology and Hepatology, University Hospital Essen, 45122 Essen, Germany
2Division of Cardiology, University Hospital Essen, 45122 Essen, Germany
3Department of Surgery, Evangelisches Krankenhaus Dinslaken, 46535 Dinslaken, Germany

Received 31 January 2011; Accepted 1 May 2011

Academic Editor: Duo Li

Copyright © 2011 Julia Kälsch et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. E. Feldstein, “Novel insights into the pathophysiology of nonalcoholic fatty liver disease,” Seminars in Liver Disease, vol. 30, no. 4, pp. 391–401, 2010. View at Publisher · View at Google Scholar
  2. O. Cheung and A. J. Sanyal, “Abnormalities of lipid metabolism in nonalcoholic fatty liver disease,” Seminars in Liver Disease, vol. 28, no. 4, pp. 351–359, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Ertle, A. Dechêne, J. P. Sowa et al., “Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis,” International Journal of Cancer, vol. 128, no. 10, pp. 2436–2443, 2011. View at Publisher · View at Google Scholar
  4. A. E. Feldstein, A. Canbay, P. Angulo et al., “Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis,” Gastroenterology, vol. 125, no. 2, pp. 437–443, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Wieckowska, N. N. Zein, L. M. Yerian, A. R. Lopez, A. J. McCullough, and A. E. Feldstein, “In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease,” Hepatology, vol. 44, no. 1, pp. 27–33, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. Yilmaz, E. Dolar, E. Ulukaya et al., “Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis,” World Journal of Gastroenterology, vol. 13, no. 6, pp. 837–844, 2007. View at Google Scholar · View at Scopus
  7. A. E. Feldstein, A. Wieckowska, A. R. Lopez, Y. C. Liu, N. N. Zein, and A. J. McCullough, “Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study,” Hepatology, vol. 50, no. 4, pp. 1072–1078, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. J. G. McHutchison, L. M. Blatt, M. de Medina et al., “Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology,” Journal of Gastroenterology and Hepatology, vol. 15, no. 8, pp. 945–951, 2000. View at Publisher · View at Google Scholar
  9. V. Nobili, A. Alisi, G. Torre et al., “Hyaluronic acid predicts hepatic fibrosis in children with nonalcoholic fatty liver disease,” Translational Research, vol. 156, no. 4, pp. 229–234, 2010. View at Publisher · View at Google Scholar
  10. D. E. Kleiner, E. M. Brunt, M. Van Natta et al., “Design and validation of a histological scoring system for nonalcoholic fatty liver disease,” Hepatology, vol. 41, no. 6, pp. 1313–1321, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. NLM, NCBI, Bethesda, Md, USA, 2011, http://www.pubmed.gov.
  12. A. Canbay, S. Friedman, and G. J. Gores, “Apoptosis: the nexus of liver injury and fibrosis,” Hepatology, vol. 39, no. 2, pp. 273–278, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. R. P. Witek, W. C. Stone, F. G. Karaca et al., “Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis,” Hepatology, vol. 50, no. 5, pp. 1421–1430, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. L. B. Seeff, G. T. Everson, T. R. Morgan et al., “Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial,” Clinical Gastroenterology and Hepatology, vol. 8, no. 10, pp. 877–883, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Harwood, P. Bishop, H. Liu, and M. Nowicki, “Safety of blind percutaneous liver biopsy in obese children a retrospective analysis,” Journal of Clinical Gastroenterology, vol. 44, no. 10, pp. e253–e255, 2010. View at Publisher · View at Google Scholar
  16. V. Ratziu, F. Charlotte, A. Heurtier et al., “Sampling variability of liver biopsy in nonalcoholic fatty liver disease,” Gastroenterology, vol. 128, no. 7, pp. 1898–1906, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. D. L. Diab, L. Yerian, P. Schauer et al., “Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients,” Clinical Gastroenterology and Hepatology, vol. 6, no. 11, pp. 1249–1254, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. L. P. Bechmann, R. K. Gieseler, J. P. Sowa et al., “Apoptosis is associated with CD36/fatty acid translocase upregulation in non-alcoholic steatohepatitis,” Liver International, vol. 30, no. 6, pp. 850–859, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Tabuchi, K. Tomioka, T. Kawakami et al., “Serum cytokeratin 18 M30 antigen level and its correlation with nutritional parameters in middle-aged Japanese males with nonalcoholic fatty liver disease (NAFLD),” Journal of Nutritional Science and Vitaminology, vol. 56, no. 5, pp. 271–278, 2010. View at Publisher · View at Google Scholar
  20. S. Tan, L. P. Bechmann, S. Benson et al., “Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 1, pp. 343–348, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. T. I. A. R. Tamimi, H. M. Elgouhari, N. Alkhouri et al., “An apoptosis panel for nonalcoholic steatohepatitis diagnosis,” Journal of Hepatology, vol. 54, no. 6, pp. 1224–1229, 2011. View at Publisher · View at Google Scholar
  22. E. Fitzpatrick, R. R. Mitry, A. Quaglia, M. J. Hussain, R. DeBruyne, and A. Dhawan, “Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD,” Journal of Pediatric Gastroenterology and Nutrition, vol. 51, no. 4, pp. 500–506, 2010. View at Publisher · View at Google Scholar
  23. R. K. Gieseler, G. Marquitan, M. Schlattjan et al., “Hepatocyte apoptotic bodies encasing nonstructural HCV proteins amplify hepatic stellate cell activation: implications for chronic hepatitis C,” Journal of Viral Hepatitis. In press.
  24. A. Canbay, A. E. Feldstein, H. Higuchi et al., “Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression,” Hepatology, vol. 38, no. 5, pp. 1188–1198, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. L. Castéra, J. Foucher, P. H. Bernard et al., “Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations,” Hepatology, vol. 51, no. 3, pp. 828–835, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. S. M. Martínez, G. Crespo, M. Navasa, and X. Forns, “Noninvasive assessment of liver fibrosis,” Hepatology, vol. 53, no. 1, pp. 325–335, 2011. View at Publisher · View at Google Scholar
  27. V. Ratziu, P. Giral, M. Munteanu et al., “Screening for liver disease using non-invasive biomarkers (fibrotest, steatotest and nashtest) in patients with hyperlipidaemia,” Alimentary Pharmacology and Therapeutics, vol. 25, no. 2, pp. 207–218, 2007. View at Publisher · View at Google Scholar · View at Scopus